|
HK1225740A1
(zh)
|
2013-08-22 |
2017-09-15 |
Acceleron Pharma Inc. |
TGF-β受体II型变体及其用途
|
|
WO2015048312A1
(en)
|
2013-09-26 |
2015-04-02 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
BR112016014952A2
(pt)
|
2014-02-10 |
2017-09-19 |
Merck Patent Gmbh |
Inibição direcionada de tgfbeta
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
KR20170060042A
(ko)
|
2014-09-13 |
2017-05-31 |
노파르티스 아게 |
Alk 억제제의 조합 요법
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
EP3770171A1
(en)
|
2015-04-03 |
2021-01-27 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
MA53355A
(fr)
|
2015-05-29 |
2022-03-16 |
Agenus Inc |
Anticorps anti-ctla-4 et leurs procédés d'utilisation
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
CN108348578B
(zh)
|
2015-08-04 |
2022-08-09 |
阿塞勒隆制药公司 |
用于治疗骨髓增生性病症的方法
|
|
WO2017020291A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
|
US20200231652A1
(en)
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
|
KR20180063885A
(ko)
|
2015-09-24 |
2018-06-12 |
더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 |
전이 감소를 위한 방법 및 조성물
|
|
US11583593B2
(en)
|
2016-01-14 |
2023-02-21 |
Synthis Therapeutics, Inc. |
Antibody-ALK5 inhibitor conjugates and their uses
|
|
US10894823B2
(en)
|
2016-03-24 |
2021-01-19 |
Gensun Biopharma Inc. |
Trispecific inhibitors for cancer treatment
|
|
AU2017268234A1
(en)
*
|
2016-05-17 |
2018-12-13 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
|
EP3464360B1
(en)
|
2016-05-27 |
2025-11-12 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
|
AU2017310027A1
(en)
*
|
2016-08-12 |
2019-01-31 |
Merck Patent Gmbh |
Combination therapy for cancer
|
|
KR102617453B1
(ko)
|
2016-09-19 |
2023-12-26 |
현대모비스 주식회사 |
보조 표지판 인식 장치 및 그 방법
|
|
BR112019005964A2
(pt)
|
2016-09-27 |
2019-06-18 |
Epicentrx, Inc. |
proteínas de fusão imunomoduladoras
|
|
JP7066696B2
(ja)
|
2016-10-11 |
2022-05-13 |
アジェナス インコーポレイテッド |
抗ｌａｇ－３抗体及びその使用方法
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
DK3551660T5
(da)
|
2016-12-07 |
2024-09-02 |
Agenus Inc |
Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
WO2018128939A1
(en)
|
2017-01-05 |
2018-07-12 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
|
WO2018129331A1
(en)
*
|
2017-01-07 |
2018-07-12 |
Merck Patent Gmbh |
Dosing regimens and dosage forms for targeted tgf-b inhibition
|
|
EP3568474A1
(en)
*
|
2017-01-10 |
2019-11-20 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
GB201700567D0
(en)
*
|
2017-01-12 |
2017-03-01 |
Genagon Therapeutics Ab |
Therapeutic agents
|
|
JP2020503883A
(ja)
|
2017-01-13 |
2020-02-06 |
アジェナス インコーポレイテッド |
Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
|
|
AU2018228435C1
(en)
|
2017-03-02 |
2025-09-18 |
National Research Council Of Canada |
TGF-beta-receptor ectodomain fusion molecules and uses thereof
|
|
RU2765997C2
(ru)
*
|
2017-03-30 |
2022-02-07 |
Мерк Патент Гмбх |
Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
|
|
KR20240017409A
(ko)
|
2017-04-13 |
2024-02-07 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
CN110709422B
(zh)
|
2017-04-19 |
2023-12-26 |
马伦戈治疗公司 |
多特异性分子及其用途
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
ES2948647T3
(es)
*
|
2017-05-04 |
2023-09-15 |
Acceleron Pharma Inc |
Proteínas de fusión del receptor TGF-beta tipo II y usos de las mismas
|
|
AU2018266103B2
(en)
*
|
2017-05-09 |
2024-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
|
|
MY202480A
(en)
*
|
2017-05-12 |
2024-04-30 |
Shanghai hengrui pharmaceutical co ltd |
Fusion protein containing tgf- receptor and medicinal uses thereof
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
CA3073055A1
(en)
|
2017-09-04 |
2019-03-07 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (mll)-specific phosphopeptides and methods of use thereof
|
|
JP2020536518A
(ja)
|
2017-09-27 |
2020-12-17 |
エピセントアールエックス，インコーポレイテッド |
免疫調節融合タンパク質
|
|
TW201923089A
(zh)
*
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
|
EP3720881A1
(en)
*
|
2017-12-08 |
2020-10-14 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
WO2019173692A2
(en)
|
2018-03-09 |
2019-09-12 |
Agenus Inc. |
Anti-cd73 antibodies and methods of use thereof
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3765019A1
(en)
|
2018-03-14 |
2021-01-20 |
Merck Patent GmbH |
Compounds and uses thereof to treat tumors in a subject
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
US12103959B2
(en)
|
2018-05-03 |
2024-10-01 |
Acceleron Pharma Inc. |
Multispecific binders of TGFBeta-superfamily ligands and uses thereof
|
|
US12168683B2
(en)
|
2018-05-03 |
2024-12-17 |
Acceleron Pharma Inc. |
Binders of TGFβ-superfamily ligands and uses thereof
|
|
MX2020011684A
(es)
|
2018-05-04 |
2020-12-10 |
Merck Patent Gmbh |
Inhibicion combinada de pd-1/pd-l1, tgfbeta y dna-pk para el tratamiento del cancer.
|
|
WO2019222252A1
(en)
*
|
2018-05-15 |
2019-11-21 |
Merck Patent Gmbh |
Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
|
|
CA3100544A1
(en)
|
2018-05-17 |
2019-11-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates
|
|
JP2021527083A
(ja)
*
|
2018-06-13 |
2021-10-11 |
メルク パテント ゲーエムベーハー |
ステージｉｉｉ ｎｓｃｌｃの治療及びその治療に伴う病理学的状態の鎮静
|
|
WO2019242505A1
(zh)
|
2018-06-17 |
2019-12-26 |
上海健信生物医药科技有限公司 |
靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
|
|
KR20210022680A
(ko)
*
|
2018-06-22 |
2021-03-03 |
메르크 파텐트 게엠베하 |
담도암의 치료에 사용하기 위한 표적화된 TGF-β 억제를 위한 투약 레지멘
|
|
US10597453B2
(en)
|
2018-06-29 |
2020-03-24 |
Gensun Biopharma, Inc. |
Antitumor immune checkpoint regulator antagonists
|
|
AU2019299318A1
(en)
*
|
2018-07-02 |
2021-01-21 |
Merck Patent Gmbh |
Combination therapy with targeted TGF-B inhibition for treatment of advanced non-small cell lung cancer
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AU2019301070B2
(en)
|
2018-07-09 |
2025-09-11 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
WO2020041607A1
(en)
*
|
2018-08-22 |
2020-02-27 |
Merck Patent Gmbh |
Treatment of triple negative breast cancer with targeted tgf-b inhibition
|
|
CN113164777B
(zh)
|
2018-09-27 |
2024-12-13 |
马伦戈治疗公司 |
Csf1r/ccr2多特异性抗体
|
|
AU2019372436A1
(en)
|
2018-11-01 |
2021-05-20 |
Merck Patent Gmbh |
Methods of administering anti-TIM-3 antibodies
|
|
WO2020093023A1
(en)
|
2018-11-01 |
2020-05-07 |
Merck Patent Gmbh |
Anti-tim-3 antibodies
|
|
US12559539B2
(en)
|
2018-11-09 |
2026-02-24 |
Jiangsu Hengrui Medicine Co., Ltd. |
TGF-beta receptor fusion protein pharmaceutical composition and use thereof
|
|
CN113226335B
(zh)
*
|
2018-12-06 |
2023-10-13 |
广东天科雅生物医药科技有限公司 |
靶向肿瘤抗原、TGF-β、和免疫检查点的组合型TCR-T细胞疗法
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
JP7737306B2
(ja)
|
2019-02-21 |
2025-09-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
|
|
US20220226491A1
(en)
|
2019-03-15 |
2022-07-21 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates Targeting PD-L1
|
|
BR112021024820A2
(pt)
*
|
2019-06-10 |
2022-01-25 |
Shandong Boan Biotechnology Co Ltd |
Proteína de fusão bifuncional contra pdl1 e tgfss e uso da mesma
|
|
US20200390899A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
CN110218260A
(zh)
*
|
2019-06-24 |
2019-09-10 |
王跃驹 |
植物作为宿主在表达m7842中的应用
|
|
CN114340735B
(zh)
*
|
2019-06-28 |
2024-11-12 |
璟尚生物制药公司 |
突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
|
|
US20210107969A1
(en)
*
|
2019-07-09 |
2021-04-15 |
The Johns Hopkins University |
Molecules, compositions and methods for treatment of cancer
|
|
CN112239507A
(zh)
|
2019-07-17 |
2021-01-19 |
鸿运华宁（杭州）生物医药有限公司 |
ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
|
|
US20220289824A1
(en)
*
|
2019-08-15 |
2022-09-15 |
Nantbio, Inc. |
TGF-beta TRAP
|
|
EP4023679A4
(en)
*
|
2019-08-30 |
2023-10-04 |
Nanjing Shunxin Pharmaceuticals Co., Ltd. of Chiatai Tianqing Pharmaceutical Group |
FUSION PROTEIN TARGETING PD-L1 AND TGF-BETA AND USE THEREOF
|
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗ｃｄ９６抗體及其使用方法
|
|
US20220313835A1
(en)
|
2019-09-03 |
2022-10-06 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
CA3151662A1
(en)
|
2019-09-04 |
2021-03-11 |
Bolt Biotherapeutics, Inc. |
Immunoconjugate synthesis method
|
|
CN112442132A
(zh)
*
|
2019-09-05 |
2021-03-05 |
复旦大学 |
靶向肿瘤的重组双功能融合蛋白及其应用
|
|
CN115947846A
(zh)
|
2019-09-12 |
2023-04-11 |
普米斯生物技术(珠海)有限公司 |
一种抗pd-l1纳米抗体及其衍生物和用途
|
|
EP4023672A1
(en)
*
|
2019-09-30 |
2022-07-06 |
Harbour Biomed (Shanghai) Co., Ltd |
Anti-pd-l1 antigen binding protein, and application thereof
|
|
US20220347310A1
(en)
|
2019-09-30 |
2022-11-03 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
CN114616251B
(zh)
*
|
2019-10-21 |
2024-05-24 |
南京维立志博生物科技有限公司 |
靶向PD-1和TGFβ的重组蛋白
|
|
TWI857167B
(zh)
|
2019-10-25 |
2024-10-01 |
美商博特生物治療公司 |
噻吩并氮呯免疫結合物及其用途
|
|
WO2021084124A1
(en)
|
2019-11-01 |
2021-05-06 |
Ares Trading S.A. |
COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
|
|
IL292758A
(en)
*
|
2019-11-05 |
2022-07-01 |
Merck Patent Gmbh |
Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
|
|
TW202128763A
(zh)
*
|
2019-11-12 |
2021-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
|
|
CN114746451A
(zh)
*
|
2019-11-27 |
2022-07-12 |
上海岸迈生物科技有限公司 |
TGFβ/PD-L1双特异性结合蛋白
|
|
BR112022010824A2
(pt)
*
|
2019-12-11 |
2022-08-23 |
Wuxi Biologics Ireland Ltd |
Anticorpo bifuncional contra pd-l1 e tgf¿
|
|
EP3838260A1
(en)
|
2019-12-20 |
2021-06-23 |
Ares Trading S.A. |
Igg:tgf rii fusion protein composition
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
JP7730817B6
(ja)
|
2019-12-20 |
2025-09-26 |
アレス トレーディング ソシエテ アノニム |
ＩｇＧ：ＴＧＦβＲＩＩ融合タンパク質組成物
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
CN114929734A
(zh)
*
|
2020-01-09 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
新型含有4-1bbl三聚体的抗原结合分子
|
|
JP2023511363A
(ja)
*
|
2020-01-21 |
2023-03-17 |
ボルト バイオセラピューティクス、インコーポレーテッド |
坑ｐｄ－ｌ１抗体
|
|
JP2023511362A
(ja)
*
|
2020-01-21 |
2023-03-17 |
ボルト バイオセラピューティクス、インコーポレーテッド |
坑ｐｄ－ｌ１抗体
|
|
US20230093512A1
(en)
*
|
2020-02-18 |
2023-03-23 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion proteins and uses thereof
|
|
EP4093779A4
(en)
*
|
2020-02-25 |
2024-03-06 |
Wuxi Biologics Ireland Limited |
BIFUNCTIONAL FUSION PROTEIN AND USES THEREOF
|
|
WO2021185337A1
(zh)
*
|
2020-03-20 |
2021-09-23 |
荣昌生物制药(烟台)股份有限公司 |
一种双特异性融合蛋白及其应用
|
|
CA3175490A1
(en)
*
|
2020-04-14 |
2021-10-21 |
Glaxosmithkline Intellectual Property Limited |
Combination treatment for cancer based upon an icos antibody and a pd-l1 antibody tgf-beta-receptor fusion protein
|
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
CN115843312A
(zh)
|
2020-04-24 |
2023-03-24 |
马伦戈治疗公司 |
结合至t细胞相关癌细胞的多功能性分子及其用途
|
|
MX2021015024A
(es)
|
2020-04-28 |
2022-01-18 |
Univ Rockefeller |
Anticuerpos anti-sars-cov-2 ampliamente neutralizantes y métodos de uso de los mismos.
|
|
BR112022022020A2
(pt)
*
|
2020-04-29 |
2023-01-31 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Proteína bifuncional contra pd-1 e tgf-ss
|
|
KR20230005907A
(ko)
|
2020-05-01 |
2023-01-10 |
볼트 바이오테라퓨틱스 인코퍼레이티드 |
항-dectin-2 항체
|
|
US20230293716A1
(en)
|
2020-05-08 |
2023-09-21 |
Bolt Biotherapeutics, Inc. |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
|
JP2023532279A
(ja)
*
|
2020-06-26 |
2023-07-27 |
ソレント・セラピューティクス・インコーポレイテッド |
免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ）
|
|
WO2022011256A1
(en)
|
2020-07-10 |
2022-01-13 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
CN113968903A
(zh)
*
|
2020-07-24 |
2022-01-25 |
迈威(上海)生物科技股份有限公司 |
TGF-β RII突变体及其融合蛋白
|
|
US11028174B1
(en)
|
2020-07-28 |
2021-06-08 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting PD-L1 and TGF-β
|
|
US20230287125A1
(en)
*
|
2020-07-28 |
2023-09-14 |
Lepu Biopharma Co., Ltd. |
Bifunctional molecules targeting pd-l1 and tgf-beta
|
|
TW202214287A
(zh)
*
|
2020-08-24 |
2022-04-16 |
大陸商江蘇恒瑞醫藥股份有限公司 |
TGF-β受體的融合蛋白與多靶點酪胺酸激酶抑制劑聯合在製備治療腫瘤藥物中的用途
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
|
GB2616354A
(en)
|
2020-08-26 |
2023-09-06 |
Marengo Therapeutics Inc |
Methods of detecting TRBC1 or TRBC2
|
|
CN115884989A
(zh)
*
|
2020-08-31 |
2023-03-31 |
杭州九源基因工程有限公司 |
靶向PD-L1和TGFβ的双功能融合蛋白及其制备方法与应用
|
|
CN114106190B
(zh)
|
2020-08-31 |
2025-04-08 |
普米斯生物技术(珠海)有限公司 |
一种抗vegf/pd-l1双特异性抗体及其用途
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
EP4165086A4
(en)
*
|
2020-09-16 |
2024-07-31 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
CN116390940A
(zh)
*
|
2020-09-23 |
2023-07-04 |
海正生物制药有限公司 |
Tgfbr2-ecd突变体及包含其的融合蛋白与应用
|
|
CN116323657B
(zh)
*
|
2020-09-24 |
2023-12-08 |
上海齐鲁制药研究中心有限公司 |
同时靶向PD-L1和TGFβ的双功能分子及其医药用途
|
|
CN114349867B
(zh)
*
|
2020-10-14 |
2024-05-28 |
广东菲鹏制药股份有限公司 |
融合蛋白及其应用
|
|
US20230372319A1
(en)
|
2020-11-02 |
2023-11-23 |
Ares Trading S.A. |
Combination Treatment of Cancer
|
|
AU2021372815A1
(en)
|
2020-11-02 |
2023-06-22 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
CN114573701A
(zh)
*
|
2020-12-02 |
2022-06-03 |
上海华奥泰生物药业股份有限公司 |
抗PD-L1/TGF-β双功能抗体及其用途
|
|
CN116635084A
(zh)
|
2020-12-11 |
2023-08-22 |
博尔特生物治疗药物有限公司 |
抗cea免疫缀合物和其用途
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
CA3200168A1
(en)
|
2020-12-11 |
2022-06-16 |
Shelley Erin ACKERMAN |
Anti-pd-l1 immunoconjugates, and uses thereof
|
|
WO2022174451A1
(zh)
|
2021-02-22 |
2022-08-25 |
浙江道尔生物科技有限公司 |
一种具有抗癌活性的多结构域融合蛋白
|
|
CA3212345A1
(en)
|
2021-03-02 |
2022-09-09 |
Glaxosmithkline Intellectual Property Development Limited |
Substituted pyridines as dnmt1 inhibitors
|
|
CN117940168A
(zh)
|
2021-03-26 |
2024-04-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
|
|
CN117769439A
(zh)
|
2021-03-26 |
2024-03-26 |
博尔特生物治疗药物有限公司 |
2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
|
|
JP2024517872A
(ja)
|
2021-05-03 |
2024-04-23 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ＨＥＲ２を標的にするＦｃ抗原結合性フラグメント－薬物抱合体
|
|
CN114773485B
(zh)
*
|
2021-05-11 |
2024-05-17 |
江苏先声药业有限公司 |
抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
|
|
IL308818A
(en)
|
2021-05-25 |
2024-01-01 |
Merck Patent Gmbh |
Egfr targeting fc antigen binding fragment-drug conjugates
|
|
EP4351640A1
(en)
|
2021-06-07 |
2024-04-17 |
Ares Trading S.A. |
Combination treatment of cancer
|
|
AU2022335237A1
(en)
*
|
2021-08-27 |
2024-03-28 |
Theranotics Co., Ltd. |
Bispecific molecule specifically binding to b7-h3 and tgfβ and uses thereof
|
|
US11945856B2
(en)
|
2022-01-28 |
2024-04-02 |
35Pharma Inc. |
Activin receptor type IIB variants and uses thereof
|
|
CN114990129B
(zh)
*
|
2022-05-11 |
2023-02-03 |
北京贝来生物科技有限公司 |
表达αPDL1:Fc融合蛋白的间充质干细胞的制备及应用
|
|
CN119213034A
(zh)
|
2022-05-17 |
2024-12-27 |
苏州创胜医药集团有限公司 |
双功能蛋白质及其制剂和用途
|
|
WO2024137619A1
(en)
|
2022-12-20 |
2024-06-27 |
Bolt Biotherapeutics, Inc. |
Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
|
|
WO2024173384A1
(en)
|
2023-02-14 |
2024-08-22 |
Bolt Biotherapeutics, Inc. |
Aza-benzazepine immunoconjugates, and uses thereof
|
|
WO2024186626A1
(en)
|
2023-03-03 |
2024-09-12 |
Bolt Biotherapeutics, Inc. |
Aza-bicyclic sting agonist immunoconjugates, and uses thereof
|
|
EP4694894A1
(en)
|
2023-04-12 |
2026-02-18 |
Agenus Inc. |
Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
|
|
WO2024216089A1
(en)
|
2023-04-13 |
2024-10-17 |
Bolt Biotherapeutics, Inc. |
Anti-dectin-2 antibody combination therapy
|
|
WO2025096770A1
(en)
*
|
2023-10-31 |
2025-05-08 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and uses thereof
|
|
WO2025110822A1
(ko)
*
|
2023-11-24 |
2025-05-30 |
주식회사 메드팩토 |
피브로넥틴 엑스트라도메인 b (extradomain b of fibronectin, edb-fn) 및 전환성장인자 베타(transforming growth factor β, tgfβ)에 특이적으로 결합하는 융합 단백질 및 이의 용도
|
|
WO2025140212A1
(en)
*
|
2023-12-26 |
2025-07-03 |
Laekna Therapeutics Shanghai Co., Ltd. |
Multispecific binding agents comprising anti-fibroblast activation protein (fap) antibodies and one or more monovalent ligand traps and uses thereof
|
|
US20260092096A1
(en)
|
2024-05-14 |
2026-04-02 |
35Pharma Inc. |
Activin receptor type iib variants and uses thereof
|
|
WO2026050214A1
(en)
|
2024-08-27 |
2026-03-05 |
Bolt Biotherapeutics, Inc. |
Anti-claudin, tlr agonist immunoconjugates and uses thereof
|
|
WO2026055185A1
(en)
|
2024-09-04 |
2026-03-12 |
Bolt Biotherapeutics, Inc. |
Sting agonist immunoconjugates and uses thereof
|